Onconetix Files Amendment to 8-K

Ticker: ONCO · Form: 8-K/A · Filed: Mar 13, 2024 · CIK: 1782107

Sentiment: neutral

Topics: amendment, financial-statements, exhibits

TL;DR

Onconetix filed an amendment to its 8-K, check for updated financial info.

AI Summary

Onconetix, Inc. filed an amendment (No. 3) to its Form 8-K on March 13, 2024, reporting an event that occurred on December 15, 2023. This amendment pertains to financial statements and exhibits, indicating a correction or addition to previously filed information. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio.

Why It Matters

This filing is an amendment to a previous report, suggesting Onconetix is correcting or supplementing information previously provided to the SEC, which could be important for investors to review.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, not a new event, and primarily concerns financial statements and exhibits.

Key Players & Entities

FAQ

What specific financial statements or exhibits are being amended?

The filing indicates that the amendment pertains to 'Financial Statements and Exhibits' but does not specify which particular statements or exhibits are being corrected or supplemented in this amendment.

What was the original event date being reported on December 15, 2023?

The filing states December 15, 2023, as the 'Date of earliest event reported' for the original Form 8-K, but the specific event is not detailed within this amendment's provided text.

Why was Amendment No. 3 filed?

The filing is an amendment to a Form 8-K, indicating a correction or addition to previously reported information concerning financial statements and exhibits.

What are the former names of Onconetix, Inc.?

Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. (name change effective April 24, 2023) and Blue Water Vaccines Inc. (name change effective July 10, 2019).

Where is Onconetix, Inc. headquartered?

Onconetix, Inc.'s principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.

Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-03-13 16:59:10

Key Financial Figures

Filing Documents

financial statements of Proteomedix required by Item 9.01(a) of Form 8-K (the " Proteomedix Financial Statements ") and

financial statements of Proteomedix required by Item 9.01(a) of Form 8-K (the " Proteomedix Financial Statements ") and the pro forma combined financial information required by Item 9.01(b) of Form 8-K that were not included in the Original Form 8-K (together with the Proteomedix Financial Statements, the " Proteomedix Financial Information ") in reliance on the instructions to such item. This Amendment No. 3 on Form 8-K/A further amends the Original Form 8-K to add as an exhibit required by Item 9.01(d) a consent from BDO AG, Proteomedix's independent registered public accounting firm (" BDO ") to incorporate by reference BDO's audit report included in the Proteomedix Financial Information into certain of the Company's registration statements. Except as described above, all other information in the Original Form 8-K remains unchanged. 1

01 Financial

Item 9.01 Financial (d) Exhibits 23.1 Consent of BDO AG. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. Date: March 12, 2024 By: /s/ Bruce Harmon Bruce Harmon Chief Financial Officer 3

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing